Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Syndax Is Skyrocketing 55% Today

TheMotleyFool

0 0

This morning Syndax Pharmaceuticals (NASDAQ: SNDX) updated investors with initial data from a phase 1/2 trial evaluating its leukemia drug, and shares are soaring 55% at 12:05 pm EST on Tuesday.

Syndax is a clincial-stage healthcare company developing cancer drugs, including SNDX-5613, a therapy for the treatment of leukemia caused by specific genetic abnormalities, including rearrangements of the MLL gene (MLL-r) and NPM1 mutation.

IMAGE SOURCE: GETTY IMAGES.

Source Fool.com

Like: 0

SNDX

Share